$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Has bimekizumab been included in medical insurance reimbursement?
2026-02-01 22:25:32
Check Details
Latest news on ensifentrine, improves dyspnea, symptoms and quality of life in patients with chronic obstructive pulmonary disease without exacerbation
2026-02-01 22:25:32
Check Details
Clinical guidelines for the scope of use of everolimus/Afinitor
2026-02-01 22:25:32
Check Details
Can I continue taking Anagrelide after taking it for 20 days?
2026-02-01 22:25:32
Check Details
Information on whether Atrasentan has been officially launched in China
2026-02-01 22:25:32
Check Details
The main mechanism of action of Elotuzumab
2026-02-01 22:25:32
Check Details
Can bimekizumab be used to treat uveitis
2026-02-01 22:25:32
Check Details
Latest official price of ensifentrine - Ohtuvayre market in 2025
2026-02-01 22:25:32
Check Details
Pyrotinib Maleate single box price and purchase channels
2026-02-01 22:25:32
Check Details
Detailed explanation of the six taboos when using Roprostim (Huierning)
2026-02-01 22:25:32
Check Details
Is Fulvestrant/Fuxit an endocrine drug?
2026-02-01 22:25:32
Check Details
Evaluation of the efficacy of Midostaurin in the clinical treatment of patients with leukemia
2026-02-01 22:25:32
Check Details
1
2
...
2235
2236
2237
2238
2239
2240
2241
...
10228
10229
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Trelagliptin: A Once-Weekly Long-Acting Oral DPP-4 Inhibitor
2
Neurokinin Receptor Antagonists: A Non-Hormonal Approach to Menopausal Hot Flashes and Sleep Disturbances
3
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
4
Nintedanib: A Multi-Target Antifibrotic Agent for Slowing Pulmonary Fibrosis Progression
5
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
6
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
7
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
8
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
9
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
10
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
11
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
12
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations